Surrozen, Inc. SRZN
We take great care to ensure that the data presented and summarized in this overview for Surrozen, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SRZN
View allLatest Institutional Activity in SRZN
Top Purchases
Top Sells
About SRZN
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Insider Transactions at SRZN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 14
2024
|
Yang Li Exec. Vice President, Research |
BUY
Grant, award, or other acquisition
|
Direct |
400
+3.54%
|
$2,000
$5.67 P/Share
|
|
Jun 14
2024
|
Charles O Williams CFO and COO |
BUY
Grant, award, or other acquisition
|
Direct |
400
+6.39%
|
$2,000
$5.67 P/Share
|
|
Jun 14
2024
|
Craig C Parker Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
400
+6.43%
|
$2,000
$5.67 P/Share
|
|
Apr 04
2024
|
Charles O Williams CFO and COO |
BUY
Open market or private purchase
|
Direct |
1,474
+50.0%
|
-
|
|
Apr 04
2024
|
Craig C Parker Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
1,474
+50.0%
|
-
|
|
Apr 04
2024
|
Column Group Iii Gp, LP |
BUY
Open market or private purchase
|
Indirect |
193,548
+23.57%
|
$2,903,220
$15.5 P/Share
|
|
Apr 04
2024
|
Tim Kutzkey |
BUY
Open market or private purchase
|
Indirect |
193,548
+23.57%
|
$2,903,220
$15.5 P/Share
|
|
Dec 15
2023
|
Yang Li Exec. Vice President, Research |
BUY
Grant, award, or other acquisition
|
Direct |
2,085
+50.0%
|
$10,425
$5.67 P/Share
|
|
Dec 15
2023
|
Charles O Williams CFO and COO |
BUY
Grant, award, or other acquisition
|
Direct |
2,085
+50.0%
|
$10,425
$5.67 P/Share
|
|
Dec 15
2023
|
Craig C Parker Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,046
+50.0%
|
$10,230
$5.67 P/Share
|
|
Jun 15
2023
|
Charles O Williams CFO and COO |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+41.96%
|
$0
$0.38 P/Share
|
|
Jun 15
2023
|
Wen Chen Yeh Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,638
+39.32%
|
$0
$0.38 P/Share
|
|
Jun 15
2023
|
Craig C Parker Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+41.96%
|
$0
$0.38 P/Share
|
|
Dec 15
2022
|
Craig C Parker Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,578
+50.0%
|
$0
$0.41 P/Share
|
|
Dec 15
2022
|
Wen Chen Yeh Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,578
+4.01%
|
$0
$0.41 P/Share
|
|
Dec 15
2022
|
Charles O Williams CFO and COO |
BUY
Grant, award, or other acquisition
|
Direct |
9,578
+50.0%
|
$0
$0.41 P/Share
|
|
Dec 15
2022
|
Geertrui Vanhove Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,578
+22.81%
|
$0
$0.41 P/Share
|
|
Dec 14
2022
|
Mitchell J Md Blutt > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
5,382,499
-100.0%
|
-
|
|
Aug 11
2021
|
Kevin Harold Livingston |
BUY
Grant, award, or other acquisition
|
Indirect |
1,885,000
+46.75%
|
-
|
|
Aug 11
2021
|
Kevin Harold Livingston |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
1,451,000
-100.0%
|
-
|
Last 12 Months Summary
| Open market or private purchase | 390K shares |
|---|---|
| Grant, award, or other acquisition | 1.2K shares |